← Evidence library

BIB_414

Telomerase / telomere length & melanoma — evidence anchor for TASK35 (patient asked re telomerase; family longevity interest). The decisive, counter-intuitive, MELANOMA-SPECIFIC fact: unlike most cancers (where SHORT telomeres → risk), melanoma is the standout where LONGER (constitutional/germline) telomeres → HIGHER risk — robust across GWAS, Mendelian randomisation, and a 2025 meta-analysis. Corollary: telomerase-ACTIVATING "anti-ageing" supplements (TA-65/cycloastragenol) are mechanistically the WRONG direction for a melanoma patient; TERT-promoter mutation is a top UV-driven somatic event…

Evidence grade

A

Tier

2 (JAMA Oncol MR landmark + 2025 Oncol Lett meta + peer-reviewed reviews; consti

Cited by tasks

15, 22a, 32, 34, 35

Identifiers

PMC9325578

↗ Follow the original source for full context

Full extracted findings & patient-implication analysis: bibliography/BIB_414/findings.md (research corpus). This page is a short context summary — not individualised medical advice.